Diagnostic Evidence Co-operatives (DECs)

The NIHR has funded four Diagnostic Evidence Co-operatives (DECs) to help generate information on the clinical and cost-effectiveness of in vitro diagnostic devices which are important in helping to improve the way diseases are diagnosed. This will help patients access the most appropriate treatments more quickly and help the NHS make the best use of its resources.

The Diagnostic Evidence Co-operatives will bring together a wide range of experts and specialists from across the NHS and industry, including clinicians and other healthcare professionals, patients, NHS commissioners and researchers and investigate a number of different clinical areas.

This initiative supports the Government’s Strategy for UK Life Sciences, which aims to provide a better environment for life sciences, improve the lives of patients and contribute to the UK’s economic growth, enabling patients to access novel treatments earlier.

Funding

The NIHR has provided £4 million funding to the following successful NHS Organisations for a four-year period starting 1 September 2013.

 

Name

Name including host organisation

Research theme

Funding for four years from September 2013

NIHR Diagnostic Evidence Co-operative Leeds

NIHR Diagnostic Evidence Co-operative Leeds at Leeds Teaching Hospitals NHS Trust

Musculoskeletal, Urological, Liver and Colorectal diseases and Oncology

£999,255

NIHR Diagnostic Evidence Co-operative London

NIHR Diagnostic Evidence Co-operative London at Imperial College Healthcare NHS Trust

Gut health, Respiratory diseases, Infectious diseases, Metabolic medicine, Cardiovascular diseases, Cancer

£993,690

NIHR Diagnostic Evidence Co-operative Newcastle

NIHR Diagnostic Evidence Co-operative Newcastle at Newcastle upon Tyne Hospitals NHS Foundation Trust

Liver diseases, Musculoskeletal diseases, Cardiovascular diseases, Infection, Transplantation, Cancer, Genetics, Respiratory

£787,869

NIHR Diagnostic Evidence Co-operative Oxford

NIHR Diagnostic Evidence Co-operative Oxford at Oxford Health NHS Foundation Trust

Horizon scanning and rapid reviews to identify new and emerging IVDs

£989,754

Aim

DECs will focus on clinical areas or themes where evidence of the clinical validity, clinical utility, cost-effectiveness and care pathway benefits of in vitro diagnostic medical devices (IVDs) has the potential to lead to improvements in healthcare services and the quality of life of NHS patients. Led by a Clinical Director, and involving multidisciplinary teams, they will facilitate collaborative working with clinicians and other healthcare professionals, the IVD industry, staff of at least one accredited provider of NHS pathology services, NHS commissioners, academic researchers including health economists, and patient-groups.

The DECs will:

  • act as a catalyst for the generation of high-quality evidence of clinical validity, clinical utility, cost effectiveness and care pathway benefits of commercially-supplied IVDs that is sought by a range of users, for example:
  1. NHS clinicians and NHS commissioners
  2. accredited providers of NHS pathology services
  3. companies involved in the CE marking and marketing of IVDs
  4. the NICE Diagnostic Assessment Programme.
  • enable collaboration between clinicians and other healthcare professionals, patients, the IVD industry, staff of at least one accredited provider of NHS pathology services, NHS commissioners, academic researchers including health economists, and patient groups.
  • create new, world-class methodologies for IVD assessment, where required.

Further Information
NIHR briefing document